Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial
Author:
van de Loosdrecht A. A.ORCID, Cremers E. M. P., Alhan C., Duetz C., in ’t Hout F. E. M., Visser-Wisselaar H. A., Chitu D. A., Verbrugge A., Cunha S. M., Ossenkoppele G. J., Janssen J. J. W. M., Klein S. K.ORCID, Vellenga E., Huls G. A., Muus P., Langemeijer S. M. C., de Greef G. E., te Boekhorst P. A. W., Raaijmakers M. H. G., van Marwijk Kooy M., Legdeur M. C., Wegman J. J., Deenik W., de Weerdt O., van Maanen-Lamme T. M., Jobse P., van Kampen R. J. W., Beeker A., Wijermans P. W., Biemond B. J., Tanis B. C., van Esser J. W. J., Schaar C. G.ORCID, Noordzij-Nooteboom H. S., Jacobs E. M. G., de Graaf A. O., Jongen-Lavrencic M., Stevens-Kroef M. J. P. L., Westers T. M., Jansen J. H.
Abstract
AbstractA randomized phase-II study was performed in low/int-1 risk MDS (IPSS) to study efficacy and safety of lenalidomide without (arm A) or with (arm B) ESA/G-CSF. In arm B, patients without erythroid response (HI-E) after 4 cycles received ESA; G-CSF was added if no HI-E was obtained by cycle 9. HI-E served as primary endpoint. Flow cytometry and next-generation sequencing were performed to identify predictors of response. The final evaluation comprised 184 patients; 84% non-del(5q), 16% isolated del(5q); median follow-up: 70.7 months. In arm A and B, 39 and 41% of patients achieved HI-E; median time-to-HI-E: 3.2 months for both arms, median duration of-HI-E: 9.8 months. HI-E was significantly lower in non-del(5q) vs. del(5q): 32% vs. 80%. The same accounted for transfusion independency-at-week 24 (16% vs. 67%), but similar in both arms. Apart from presence of del(5q), high percentages of bone marrow lymphocytes and progenitor B-cells, a low number of mutations, absence of ring sideroblasts, and SF3B1 mutations predicted HI-E. In conclusion, lenalidomide induced HI-E in patients with non-del(5q) and del(5q) MDS without additional effect of ESA/G-CSF. The identified predictors of response may guide application of lenalidomide in lower-risk MDS in the era of precision medicine. (EudraCT 2008-002195-10).
Funder
KWF Kankerbestrijding This study was financially supported by BMS/Celgene and Roche. BMS/Celgene and Roche had no role in the design, analysis and interpretation of the results nor in writing of the article
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference40 articles.
1. Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, Del Canizo C, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122:2943–64. 2. Jadersten M, Malcovati L, Dybedal I, Della Porta MG, Invernizzi R, Montgomery SM, et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol. 2008;26:3607–13. 3. Hellström-Lindberg E, van de Loosdrecht A. Erythropoiesis stimulating agents and other growth factors in low-risk MDS. Best Pract Res Clin Haematol. 2013;26:401–10. 4. Park S, Greenberg P, Yucel A, Farmer C, O’Neill F, De Oliveira Brandao C, et al. Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review. Br J Haematol. 2019;184:134–60. 5. Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011;118:3765–76.
|
|